GlaxoSmithKline plc’s Dividend Prospects For 2014 And Beyond

G A Chester analyses the income outlook for GlaxoSmithKline plc (LON:GSK).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Many top FTSE 100 companies are currently offering dividends that knock spots off the interest you can get from cash or bonds.

In this festive series of articles, I’m assessing how the companies measure up as income-generators, by looking at dividends past, dividends present and dividends yet to come.

Today, it’s the turn of pharmaceuticals giant GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US).

Should you invest £1,000 in Unilever right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Unilever made the list?

See the 6 stocks

Dividends past

The table below shows GSK’s five-year dividend record.

  2008 2009 2010 2011 2012
Dividend per share 57p 61p 65p 70p 74p
Dividend growth 7.5% 7.0% 6.6% 7.7% 5.7%

As you can see, GSK has increased its dividend at a fairly steady rate over the last five years. The average annual increase comes out at 6.9% — well ahead of inflation.

This has been a difficult period for GSK. Earnings have been under pressure from cutbacks in government healthcare budgets, expiring patents on some of GSK’s major products, company restructuring costs and some hefty legal settlements.

Despite these negatives, the total of 327p a share paid in dividends over the last five years has been covered 1.3 times by warts-and-all statutory earnings per share (EPS) of 427p. For the latest year (2012), statutory EPS cover of the 74p dividend was in line with the overall 1.3, while cover was 1.5 based on GSK’s ‘core’ (underlying) EPS of 112.7p.

A solid dividend performance through testing times.

Dividends present

GSK has so far paid three quarterly dividends totaling 55p for the current year. Most analysts are expecting a final dividend of 23p when the company announces its annual results on 5 February — giving a 2013 full-year payout of 78p (up 5.4% on 2012). Core EPS is expected to be modestly ahead of last year, maintaining dividend cover at around the 1.5 level.

At a share price of 1,620p, GSK’s current-year dividend represents a yield of 4.8%.

Dividends yet to come

Analysts are forecasting GSK’s dividend to rise by 5.1% to 82p for 2014, which suggests the following schedule:

  Q1 Q2 Q3 Q4
Provisional announcement date 30 April 23 July 22 October February 2015
Forecast amount 19p 19p 20p 24p

Again, analysts expect core EPS to be modestly ahead of the previous year, maintaining dividend cover at around the 1.5 level.

Looking further ahead, GSK is over the hump of its patent expiries, has a strong pipeline of new products coming to market, and management has identified £1bn of new annual cost savings by 2016.

Shareholders can be optimistic about continued annual dividend increases ahead of inflation.

5 stocks for trying to build wealth after 50

The cost of living crisis shows no signs of slowing… the conflict in the Middle East and Ukraine shows no sign of resolution, while the global economy could be teetering on the brink of recession.

Whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times. Yet despite the stock market’s recent gains, we think many shares still trade at a discount to their true value.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. We believe these stocks could be a great fit for any well-diversified portfolio with the goal of building wealth in your 50’s.

Claim your free copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

> G A Chester does not own any shares mentioned in this article. The Motley Fool has recommended shares in GlaxoSmithKline.

More on Investing Articles

Investing Articles

At a 52-week low but forecast to rise 73%! Is this growth share the FTSE’s top recovery play? 

This FTSE 100 growth share has taken an absolute beating over the past two years but Harvey Jones says the…

Read more »

Investing Articles

This FTSE 250 share offers a juicy 9.8% yield. Will it last?

This well-known FTSE 250 share has a percentage dividend yield approaching double digits. Should Christopher Ruane add the income share…

Read more »

Investing Articles

Is a £333,000 portfolio enough to retire and live off passive income?

A third of a million pounds can generate a serious amount of passive income, but relying on this sum alone…

Read more »

The flag of the United States of America flying in front of the Capitol building
Investing For Beginners

Why FTSE 100 investors should pay attention to ‘Liberation Day’

Jon Smith explains why the upcoming tariff announcement from across the pond could have an impact on the FTSE 100,…

Read more »

Concept of two young professional men looking at a screen in a technological data centre
Investing Articles

Here’s why Nvidia stock fell 13% in March

The Nvidia stock price rise was looking unstoppable. Should investors now be wondering if the same might be true of…

Read more »

US Stock

It’s ISA deadline week! Here’s my 3-step game plan

Jon Smith tries to calm the hype around the last minute ISA rush to buy stocks and explains why he's…

Read more »

Snowing on Jubilee Gardens in London at dusk
Investing Articles

£10,000 invested in BAE Systems shares at Christmas is now worth…

BAE Systems shares have been surging in the FTSE 100 in 2025, driven higher by the wavering US commitment to…

Read more »

Investing Articles

Up 19% in 2 weeks, can the Tesla share price rebound further?

Tesla's first-quarter delivery numbers came out today. Will they help persuade our writer to invest his money at the current…

Read more »